VRDN vs IMVT vs RDVT vs KYMR vs PRAX

For growth investors, Viridian Therapeutics, Inc.

(VRDN) is the stronger pick with 233. 6% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Red Violet, Inc. (RDVT) offers the better valuation at 54. 6x trailing P/E (33. 5x forward), making it the more compelling value choice. Analysts rate Viridian Therapeutics, Inc. (VRDN) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Red Violet, Inc.

(RDVT) delivered a total return of +170. 1%, compared to -14. 9% for Praxis Precision Medicines, Inc. (PRAX). Over 10 years, the gap is even starker: IMVT returned +190. 9% versus VRDN's -88. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.

(KYMR) is the lower-risk stock at 1. 03β versus Praxis Precision Medicines, Inc. 's 1. 40β — meaning PRAX is approximately 36% more volatile than KYMR relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 7% for Viridian Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Viridian Therapeutics, Inc.

(VRDN) is pulling ahead at 233. 6% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Red Violet, Inc. grew EPS 82. 0% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, VRDN leads at 241. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Red Violet, Inc.

(RDVT) is the more profitable company, earning 14. 6% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 14. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RDVT leads at 14. 6% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — VRDN leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for VRDN: 145.

1% to $40. 71.

In this comparison, RDVT (0.

6% yield) pays a dividend. VRDN, IMVT, KYMR, PRAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Red Violet, Inc.

(RDVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), 0. 6% yield). Both have compounded well over 10 years (RDVT: +7. 8%, PRAX: -20. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (VRDN (Healthcare) and IMVT (Healthcare) and RDVT (Technology) and KYMR (Healthcare) and PRAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: VRDN is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; RDVT is a small-cap high-growth stock; KYMR is a small-cap quality compounder stock; PRAX is a small-cap quality compounder stock. RDVT pays a dividend while VRDN, IMVT, KYMR, PRAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.